Delving into the Latest Updates on Cinepazide Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Anjieli, Cinepazide maleate (JAN), Kelinao

+ [4]

Target

VDCCs

Mechanism

VDCCs blockers(Voltage-gated calcium channel blockers)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Perioperative ischaemiaCerebrovascular DisordersPeripheral Vascular Diseases

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Jilin Huikang Pharmaceutical Co., Ltd.

Beijing Sihuan Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (09 Apr 2002),

Cerebrovascular DisordersPeripheral Vascular Diseases

Regulation-

Login to view timeline

Structure

Molecular FormulaC26H35N3O9

InChIKeyXSTJTOKYCAJVMJ-BTJKTKAUSA-N

CAS Registry26328-04-1

View All Structures (2)

This study aimed to investigate the therapeutic effects of cinepazide maleate (CM) on spinal cord injury (SCI) in rats, thereby providing an experimental basis for the use of CM as a preventative and therapeutic strategy for SCI. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining and western blot analysis were used to assess neural cell apoptosis. enzyme-linked immunosorbent assay was used to analyze the expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) in spinal cord tissues and cerebrospinal fluid. CD68 staining and western blot analysis were used to investigate the effect of CM on microglia activation. The effects of CM on motor function and histological damage in rats after SCI were investigated using the Basso-Beattie-Bresnahan (BBB) score, footprint assay, hematoxylin and eosin staining, and NeuN staining. In vitro models of neuronal cell injury and microglial inflammation were developed to investigate the effects of CM on apoptosis and inflammation. Functional tests (BBB score and footprint test) revealed that CM-treated rats had significantly improved motor function. In vivo CM treatment reduced the number of apoptotic cells at the site of injury. Similarly, in vitro CM treatment reduced H₂ O₂ -induced neuronal apoptosis. In vivo CM treatment reduced the number of CD68-positive microglia and the expression levels of TNF-α, IL-1β, and IL-6. Similarly, in vitro CM treatment reduced LPS-induced pro-inflammatory cytokines in microglia. CM promotes the recovery of motor function by inhibiting SCI-induced apoptosis and inflammatory responses and reducing the area of the post-SCI cavity in rats. These findings indicate that CM is a potential drug worthy of translational studies for SCI treatment.

01 Aug 2022·Zhonghua nei ke za zhi

[Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension].

Article

Author: Yang, Y ; Yi, F ; Yu, X F ; Ding, J P ; Zhang, Z B ; Chen, G F ; Wu, J ; Wang, J F ; Zhu, R X ; Li, X H ; Chen, H S ; Ji, Y ; Ni, J ; Wei, Y ; Huang, Y N ; Liu, Y F ; Lyu, H ; Cui, L Y ; Han, S G ; Gong, T ; Xiao, B ; Huang, Y H ; Cai, X L ; Qu, X H ; Geng, D Q ; Shao, B

Objective: To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection. Methods: This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke: a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate or control, which were assessed during the treatment period (14 days), and the proportion of the patients with normal blood pressure was analyzed after the treatment period. Furthermore, a subgroup analysis was performed to investigate a possible effect of the history of hypertension on outcomes. Results: This analysis included 809 patients with hypertension. There was no significant difference in patients blood pressure and the proportion of patients with normal blood pressure (60.5% vs. 59.0%,P>0.05) between cinepazide maleate group and control group. Conclusion: Administration of cinepazide maleate injection does not affect the management of clinical blood pressure in patients with AIS.

28 Oct 2021·Evidence-Based Complementary and Alternative MedicineQ4 · MEDICINE

Effect of Cinepazide Maleate on Serum Inflammatory Factors of ICU Patients with Severe Cerebral Hemorrhage after Surgery

Q4 · MEDICINE

ArticleOA

Author: Zhang, Xia ; Zhang, Jing ; Shang, Yun ; Zhang, Li

Objective. To explore the effect of cinepazide maleate on serum inflammatory factors of intensive care unit (ICU) patients with severe cerebral hemorrhage after surgery. Methods. 116 ICU patients with severe cerebral hemorrhage treated in Taian Maternal and Child Health Hospital from June 2018 to June 2020 were selected as the research objects and randomly divided into the control group and experimental group, with 58 patients in each group. The control group was given routine treatment, while the experimental group was additionally given an intravenous drip of cinepazide maleate to compare the clinical efficacy and serum inflammatory factors between the two groups. Results. The total effective rate in the experimental group was higher than that in the control group (

P < 0.05

). After treatment, the Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), and Fugl-Meyer scores in both groups were better than those before treatment, and the scores in the experimental group were better than those in the control group (

P < 0.05

). The oxidative stress indexes such as total antioxidant capacity (T-Aoc), superoxide dismutase (SOD), and glutathione peroxidase (GSH-PX) in the experimental group were higher than those in the control group, while malondialdehyde (MDA) in the experimental group was lower than that in the control group (

P < 0.05

). The high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α) levels in the experimental group were lower than those in the control group (

P < 0.05

). Compared with the control group, the cerebrovascular function in the experimental group was significantly improved (

P < 0.05

), with statistically significant differences. Conclusion. Cinepazide maleate can effectively reduce the serum inflammatory factor levels of ICU patients with severe cerebral hemorrhage after surgery, alleviate the oxidative stress response in the body, and improve the cerebrovascular function and cerebral nerve function, which is worthy of clinical promotion.

100 Deals associated with Cinepazide Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01944	Cinepazide Maleate	C04AX27	DB12123

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Perioperative ischaemia	CN	Beijing Sihuan Pharmaceutical Co. Ltd.	13 Dec 2002
Cerebrovascular Disorders	CN	Jilin Huikang Pharmaceutical Co., Ltd.	09 Apr 2002
Peripheral Vascular Diseases	CN	Jilin Huikang Pharmaceutical Co., Ltd.	09 Apr 2002